


Claims

1. A compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein:



R^1 is selected from the group consisting of a hydrogen, halogen, C_{1-4} haloalkyl, cyano,

5 C_{3-6} cycloalkyl, and C_{1-4} alkyl;

R^2 is selected from the group consisting of hydrogen, halogen, C_{1-4} haloalkyl, cyano, C_{3-6} cycloalkyl, and C_{1-4} alkyl;

R^3 is selected from the group consisting of hydrogen, halogen, C_{1-4} haloalkyl, cyano, C_{3-6} cycloalkyl, and C_{1-4} alkyl;

10 R^4 is selected from the group consisting of hydrogen, halogen, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} hydroxyhaloalkyl, cyano, NR^aR^b , SR^cR^d , OR^6 , $L-(OR^6)$, and R^7 ;

R^a and R^b are independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

R^c and R^d are independently selected from the group consisting of hydrogen and C_{1-4} alkyl;

R^6 is selected from the group consisting of hydrogen, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} hydroxyalkyl, and C_{1-4} hydroxyhaloalkyl;

L represents a C_{1-3} alkylene; and

R^7 is selected from the group consisting of C_{3-6} cycloalkyl, phenyl, 4, 5, or 6 membered heterocycle, and 5 or 6 membered heteroaryl, wherein said cycloalkyl, phenyl,

20

heterocycle or heteroaryl are independently unsubstituted or substituted with 1, 2 or 3 substituents independently selected from halogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, wherein said C₁₋₃ alkyl and C₁₋₃ alkoxy are independently unsubstituted or substituted with 1, 2 or 3 F.

- 5 2. The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R¹ is selected from the group consisting of a hydrogen, halogen, and C₁₋₄ alkyl;

R² is selected from the group consisting of hydrogen, halogen, and C₁₋₄ alkyl;

R³ is selected from the group consisting of hydrogen, halogen, and C₁₋₄ alkyl;

- 10 R⁴ is selected from the group consisting of hydrogen, halogen, C₁₋₄ alkyl, C₁₋₄ haloalkyl, C₁₋₄ hydroxyalkyl, OR⁶, and R⁷;

R⁶ is selected from the group consisting of C₁₋₄ alkyl, and C₁₋₄ haloalkyl; and

- 15 R⁷ is selected from the group consisting of a C₃₋₆ cycloalkyl and phenyl, wherein said cycloalkyl and phenyl is independently unsubstituted or substituted with 1, 2 or 3 substituents independently selected from halogen, C₁₋₃ alkyl, C₁₋₃ alkoxy, wherein said C₁₋₃ alkyl and C₁₋₃ alkoxy are independently unsubstituted or substituted with 1, 2 or 3 F.

3. The compound according to any one of claims 1 to 2, or a pharmaceutically acceptable salt thereof, wherein R¹ is hydrogen.

- 20 4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein R² is hydrogen.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein R³ is selected from the group consisting of
25 hydrogen, C₁₋₄ alkyl, and halogen.

6. The compound according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R^3 is selected from the group consisting of hydrogen, fluoro, and methyl.
7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of C_{1-4} alkyl, C_{1-4} fluoroalkyl, C_{3-6} cycloalkyl, C_{1-4} hydroxyalkyl, C_{1-4} alkoxy, NR^aR^b , SR^cR^d , halogen, and phenyl unsubstituted or substituted with ethyl.
8. The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof, wherein R^4 is selected from the group consisting of methyl, ethyl, isopropyl, fluoromethyl, difluoromethyl, trifluoromethyl, hydroxymethyl, isopropoxy, ethoxy, methoxy, cyclopropyl, fluoro, bromo, dimethylamino, methylthio, and ethylphenyl.
9. The compound according to claim 1 selected from the group consisting of:
- (R)-2-amino-3-[[7-thieno[3,2-b]pyridine-2-carbonyl]amino]propanoic acid;
- (R)-2-amino-3-[(7-ethylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;
- (R)-2-amino-3-[[7-(difluoromethyl)thieno[3,2-b]pyridine-2-carbonyl]amino]propanoic acid;
- (R)-2-amino-3-[(7-cyclopropylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;
- (R)-2-amino-3-[(7-methylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;
- (R)-2-amino-3-[(7-isopropylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;
- (R)-2-amino-3-[[7-(2-ethylphenyl)thieno[3,2-b]pyridine-2-carbonyl]amino]propanoic acid;
- (R)-2-amino-3-[(7-methoxythieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;

(R)-2-amino-3-[[7-(trifluoromethyl)thieno[3,2-b]pyridine-2-carbonyl]amino]propanoic acid;

(R)-2-amino-3-[(7-ethoxythieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;

(R)-2-amino-3-[(7-isopropoxythieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;

5 (R)-2-amino-3-[(7-bromothieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;

(R)-2-amino-3-[(7-hydroxymethylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid;

(R)-2-amino-3-[[7-(fluoromethyl)thieno[3,2-b]pyridine-2-carbonyl]amino]propanoic acid;

10 (R)-2-amino-3-[(6-fluoro-7-methyl-thieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid; and

(R)-2-amino-3-[(6,7-dimethylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid; or a pharmaceutically acceptable salt thereof.

15 10. The compound according to claim 1 wherein the compound is
(R)-2-amino-3-[(7-methylthieno[3,2-b]pyridine-2-carbonyl)amino]propanoic acid, or
a pharmaceutically acceptable salt thereof.

20 11. A pharmaceutical composition comprising a compound, or a pharmaceutically
acceptable salt thereof, according to any one of claims 1 to 10, and one or more
pharmaceutically acceptable carriers or diluents.

12. The compound or a pharmaceutically acceptable salt thereof according to any one
of claims 1 to 10 for use as a medicament.

13. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, or the pharmaceutical composition according to claim 11 for use in the treatment of depression.
- 5 14. The compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, or the pharmaceutical composition according to claim 11 for use in the treatment of a condition selected from suicidal ideation, bipolar disorder (including bipolar depression), obsessive compulsive disorder and status epilepticus.
- 10 15. Use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 10, or the pharmaceutical composition according to claim 11 for the manufacture of a medicament for use in the treatment of depression.